- Resource Centers
Roxane Laboratories Inc (Columbus, Ohio) recently announced the approval of Lithium Carbonate Extended Release Tablets USP, 450 mg. This product is ABrated to GlaxoSmithKline?s Eskalith CR (lithium carbonate) 450 mg. Lithium Carbonate Extended Release Tablets are indicated for the treatment of manic episodes of manic?depressive illness. Maintenance therapy prevents or diminishes the intensity of subsequent episodes in those manic?depressive patients with a history of mania. The tablets may produce a normalization of symptomatology within 1 to 3 weeks. For more information, visit www.roxane.com.